PBS0.F Precision BioSciences, Inc.
- Market cap
- EUR 311M
- P/E
- 37.0x
- P/B
- 6.62x
- ROE
- -151.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PBS0.F undervalued?
Graham numberThe Graham number of Precision BioSciences, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Precision BioSciences, Inc. fundamental analysis
No fundamental analysis for Precision BioSciences, Inc. yet.
Precision BioSciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate inte…
Full company profilePrecision BioSciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Precision BioSciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 116M | 25.1M | 48.7M | 68.7M | 34.3M | 14.5M |
| Operating Income | -39.4M | -62.3M | -43.7M | -26.2M | -52.1M | -64.9M |
| EBITDA | - | -62.8M | -32.0M | 13.5M | -42.4M | -74.6M |
| Net Income | -30.6M | -112M | -61.3M | 7.17M | -45.7M | -78.2M |
| EPS | -15 | -30 | -15 | 0.87 | -1.90 | -2.80 |
| Balance Sheet | ||||||
| Total Assets | 211M | 238M | 160M | 136M | 154M | 120M |
| Total Liabilities | 120M | 178M | 141M | 80.0M | 62.2M | 68.6M |
| Shareholders' Equity | 91.2M | 60.4M | 18.9M | 56.4M | 92.2M | 51.8M |
| Cash & Short-term Investments | 144M | 190M | 117M | 85.9M | 111M | 81.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.9M | -45.8M | -84.1M | -58.4M | -65.8M | -54.0M |
| Capital Expenditure | 5.80M | 3.32M | 2.28M | 275K | 700K | 424K |
| Free Cash Flow | -16.7M | -49.1M | -86.4M | -58.7M | -66.5M | -54.4M |
| Ratios | ||||||
| ROE | -33.6% | -184.7% | -325.1% | 12.7% | -49.6% | -151.1% |
| ROA | -14.5% | -46.9% | -38.4% | 5.3% | -29.6% | -65.0% |
| Net Profit Margin | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% | -541.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Precision BioSciences, Inc. dividends
Precision BioSciences, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:30 on Feb 14, 2024.
Who owns Precision BioSciences, Inc.
- Insiders 5.82%
- Institutions 46.97%
- Public & others 47.20%
- Shares outstanding 38.2M
- Free float 26.4M
Precision BioSciences, Inc. company profile
- Company name
- Precision BioSciences, Inc.
- Ticker
- PBS0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 302 East Pettigrew St., Durham, NC, United States, 27701
- Phone
- 919 314 5512
- Website
- precisionbiosciences.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences, Inc. management
10- Mr. Michael AmorosoPresident, CEO & Director · born 1978
- Mr. John Alexander Kelly R.Ph.Chief Operating Officer · born 1967
- Mr. Dario Scimeca J.D.Chief Legal Officer & Secretary · born 1975
- Dr. Jefferson J. Smith Ph.D.Co-Founder & Chief Research Officer · born 1973
- Mr. Naresh TannaChief Financial Officer · born 1981
- Ms. Mei BurrisVP of Finance & Chief Accounting Officer · born 1986
- Dr. Cassie Gorsuch Ph.D.Chief Scientific Officer
- Ms. Juli BlancheChief People Officer
- Ms. Cindy AtwellChief Development Officer
- Mr. Neil Leatherbury M.S.Senior VP and Head of Chemistry, Manufacturing & Controls